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Abstract 
Genetic and environmental factors jointly determine the susceptibility to 
develop Multiple Sclerosis (MS). Collaborative efforts during the past years 
achieved substantial progress in defining the genetic architecture, underlying 
susceptibility to MS. Similar to other autoimmune diseases, HLA-DR and 
HLA-DQ alleles within the HLA class II region on chromosome 6p21 are the 
highest-risk-conferring genes. Less-robust susceptibility effects have been 
identified for MHC class I alleles and for non-MHC regions. The role of 
environmental risk factors and their interaction with genetic susceptibility 
alleles are much less well defined, despite the fact that infections have long 
been associated with MS development. Current data suggest that infectious 
triggers are most likely ubiquitous, i.e. highly prevalent in the general 
population, and that they require a permissive genetic trait which predisposes 
for MS development. In this review article, we illustrate mechanisms of 
infection-induced immunopathologies in experimental animal models of 
autoimmune CNS inflammation, discuss challenges for the translation of 
these experimental data into human immunology research, and provide future 
perspectives on how novel model systems could be utilized to better define 
the role of viral pathogens in MS. 
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Introduction 
Multiple Sclerosis (MS) is a chronic inflammatory disease of the central 
nervous system (CNS) which usually begins in early adulthood and is 
characterized by tissue inflammation, demyelination and gliosis, various 
degrees of axonal pathology and episodic or progressive neurological 
disability. More than 1.5 million people worldwide and at least 400,000 
individuals in Europe alone are affected by MS, which is second only to 
trauma as a cause of acquired disability in young adults in most Caucasian 
populations [1]. 
 
Genetic and environmental factors jointly determine the susceptibility to 
develop MS. Collaborative efforts during the past years achieved substantial 
progress in identifying genetic risk factors that predispose for MS [2]. HLA-DR 
and HLA-DQ alleles of the HLA class II region on chromosome 6p21 are the 
highest-risk-conferring genes for most major autoimmune diseases including 
MS which is particularly associated with the DRB1*1501 allele encoding HLA-
DR2b. Less-robust susceptibility effects have been identified for MHC class I 
alleles and in non-MHC regions. The role of environmental as opposed to 
genetic risk factors in MS is much less well defined, despite the fact that 
infections have long been thought to critically contribute to disease 
development. In 1894 Pierre Marie, a former student of Charcot, argued 
strongly that infection was the cause of multiple sclerosis. He felt that 
infectious pathogens, or more likely combined infections, initiate MS [3]: 
“These gentlemen, are suppositions, and I put them before you without 
unreasonably insisting upon them. The one point in this discussion which I 
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would fix in your minds is the following fact, a fact, thank God, has been well 
established, viz., that the cause of insular sclerosis in intimately connected 
with infectious diseases.” More than a century later, intriguing epidemiological 
but weak immunological and virological evidence has resulted in a bewildering 
list of usual suspects including measles, rabies, scrapie-like agent, Carp 
agent, paramyxovirus, coronavirus, Epstein-Barr virus, herpes zoster, herpes 
simplex virus, human herpesvirus 6, rubella, mumps, canine distemper, 
Marek's Semliki forest virus, animal and human retroviruses, and human T 
cell lymphoma virus type I. Almost universally, these associations have later 
not withstood scrutiny. Such unclarity and vagueness spurred the notion that 
a pathogenic role of infectious agents in MS cannot be established unless 
experiments provide unequivocal evidence that the postulates of Koch have 
been met. 
 
Traditionally, microbiologists have used postulates formulated by Robert Koch 
and Friedrich Loeffler to demonstrate whether a particular microbe causes a 
specific disease: a microorganism must be (1) found in abundance in all 
organisms suffering from the disease, but should not be found in healthy 
animals, (2) isolated from the host with the disease and grown in pure culture, 
(3) the specific disease must be reproduced when a pure culture of the 
microbe is inoculated into a healthy susceptible host, and (4) the pathogen 
must be recoverable from the experimentally infected host [4]. These 
postulates retain historical importance, but fulfillment of all four postulates is 
not required to demonstrate causality, even in infectious diseases. Indeed, 
Koch applied these criteria in the 19th century to establish the etiology of 
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tuberculosis, but he abandoned the universalist requirement of the first 
postulate when he discovered asymptomatic carriers of cholera [5]. Likewise, 
not all individuals exposed to M. tuberculosis become infected, and 
progression towards clinical tuberculosis is far from an inevitable 
consequence of infection with Mycobacterium (M.) tuberculosis, since only 
~10% of the vast number of infected individuals actually develop clinical 
disease [6]. Such observations led to the development of the field of human 
genetics of infectious diseases and the identification of genetic traits that 
predispose to infection and clinical disease development [7]. The insight that 
clinical infectious diseases result from complex interactions between the 
infectious agent, the environment and host factors rather than following a 
simple ‘one organism-one disease paradigm’ has implications for our 
understanding of how infectious pathogens might trigger complex 
autoimmune diseases such as MS. Current data suggest that infectious 
agents that contribute to MS development are most likely ubiquitous and 
highly prevalent in the general population. Moreover, they require a 
permissive genetic trait that determines the susceptibility of the host to 
develop MS. Finally, the distinct conditions, under which primary infection with 
these pathogens is encountered, might further modulate disease risk. Here, 
we review new data for an association of certain infectious pathogens with MS 
and illustrate mechanisms of infection-induced immunopathologies in 
experimental animal models of autoimmune CNS inflammation.  
 
Multiple Sclerosis: Genes and Environment  
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MS is a relatively common disease in Europe, the United States, Canada, 
New Zealand, and parts of Australia and its prevalence generally follows a 
north to south gradient on the northern hemisphere and the opposite on the 
southern with very low rates or virtually absence of the disease near the 
equator. This geographic distribution can be attributed to both genetic effects 
and environmental influences. Arguing for the genetic hypothesis, the 
prevalence of MS differs strikingly between geographically close, but 
genetically distinct populations. Ethnic groups like Lapps in Scandinavia, 
Gypsies in Hungary, Maoris in New Zealand, or Aborigines in Australia are 
rarely or virtually not affected by MS, although the disease is otherwise 
common in these latitudes. Similarly, MS is rare among Japanese, Chinese, 
African Blacks, North and South Amerindians, and the native population in 
southern countries of the former Soviet Union, but occurs notably more 
frequently among Caucasians living in the same area. Further examples are 
the different prevalence rates in genetically distant populations living on the 
same island as it has been reported for Sardinia, Cyprus and Ireland [8].  
 
Familial aggregation studies including twins, siblings and adoptees 
demonstrated that the risk to develop MS increases with the degree of 
relatedness between individuals. For example, monozygotic twins of patients 
with MS have a more than 100 times higher risk to develop the disease and 
full-siblings have an approximately 20 times increased lifetime risk compared 
to the general population [9], [10]. While these recurrence risk values are 
considerably lower than the ones for a Mendelian-dominant disorders such as 
Huntington’s disease (approximately 5,000 fold increased risk for siblings), 
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they are similar to the risks that have been reported for other complex 
polygenic diseases such as type 1 diabetes (approximately times 20 
increased risk for siblings).  
 
An elegant approach to dissect the impact of genetic sharing versus a shared 
family environment for the development of MS are epidemiological studies on 
adoptees (no shared genes) and half-siblings compared to full-siblings (25% 
and 50% shared genes, respectively). Adopted relatives, although raised from 
infancy with the MS patients, do not develop MS more frequently than it would 
be expected for the general population [9]. Half-siblings raised apart (different 
environments) or together (same environment) with MS patients have similar 
risk to develop the disease and the recurrence risk for half-siblings is 
significantly lower than that for full-siblings raised in the same family (1.32% 
vs. 3.46%) [10].  
 
These studies made clear that the excess of the disease in biological relatives 
results from the sharing of genetic material, but does not follow a simple 
Mendelian mode of inheritance. Another important conclusion that can be 
drawn from these observations is that any non-genetic, environmental factor 
is likely to be ubiquitous and not confined to the family microenvironment [11].  
 
The concordance rate for MS is approximately 25-30% for monozygotic and 
2-5% for dizygotic twins. Although studies on animal models of autoimmune 
disease demonstrated that the rate of disease-expression can be titrated by 
the number of disease associated genes under identical environmental 
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influences [12], indicating that a simple concordance rate does not optimally 
reflect and might, indeed, underestimate the contribution of genetic factors to 
autoimmune disease development, the fact that most monozygotic twins are 
discordant for MS clearly points towards an important role of environmental 
factors in the evolution of MS. 
 
Environmental contributions are further supported by migration studies. The 
incidence of MS in migrants tends to be intermediate between that of their 
birthplace and that of their final residence, and close to the latter when 
migration occurs in childhood [13]. As pointed out by Ascherio & Munger [13], 
the risk to develop MS declines among individuals migrating from high- to low-
prevalence areas, [14], [15], [16] but does not consistently increase with 
migration in the opposite direction. As an example, first generation immigrants 
from the Caribbean and Asia whose genetic susceptibility is proven by the 
high rates of MS among their UK-born children [17], [18] rarely develop MS 
themselves suggesting that individuals born in low-risk areas appear to 
benefit from some long-lasting protection that is, however, not transmitted to 
their children [13]. 
 
Taken together, familial aggregation and migration studies indicate that 
exposure to environmental factors in childhood, and possibly during adult life, 
appear to be strong determinants of MS risk. The nature of such trigger 
factors could be both infectious and non-infectious. In this review, we focus on 
mechanisms of infection-induced pathology in MS.   
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Mechanisms  
Several mechanisms have been proposed to explain how pathogens such as 
viruses might trigger autoreactive immune responses in MS. These include 
virus-induced general activation of the immune system and the provision of 
viral gene products that specifically stimulate immune responses which cross-
react with self antigen (Figure 1).  
 
Mechanisms of bystander activation. Infectious agents express specific 
pathogen-associated molecular patterns (PAMPs). These are recognized by 
immune cell receptors leading to cellular activation, which increases the 
antigen-presenting capacity and the expression of co-stimulatory molecules 
by antigen-presenting cells (APCs), as well as their production of type I 
interferons, pro-inflammatory cytokines and chemokines, which in turn initiate 
and direct the immune response against the invading pathogen. Thus, 
pathogens are recognized as adjuvants for the immune response against 
them and could, via pattern recognition receptor (PRR)-mediated activation of 
APCs that contain self antigens obtained from dying cells or tissue damage, 
activate autoreactive T and B cells. Alternatively, the Th1-driven environment 
during viral infection could facilitate activation of autoreactive bystander T and 
B cells via proinflammatory cytokine production. An even broader form of 
bystander activation is achieved by microbial superantigens, which cross-link 
MHC class II molecules with TCRs that contain a certain V domain, leading 
to T-cell activation independently of specific antigen recognition. 
Staphylococcal, mycoplasma, endogenous retrovirus-derived and enteric 
 10
microbiota-generated superantigens were suggested to be involved in the 
disease exacerbation in animal models of MS [19].  
 
Mechanisms of molecular mimicry. Polyspecific antigen recognition has 
emerged as a fundamental feature of adaptive cellular immune responses. 
Mathematical models indicated that the TCR repertoire is not large enough to 
give functional protection against all possible foreign epitopes on the basis of 
a one-TCR-one-epitope model, and several groups consistently demonstrated 
that there can be considerable flexibility in TCR recognition of peptide-major 
histocompatibility complex (MHC) complexes [20], [21], [22], [23], [24]. 
Polyspecific or so-called degenerate TCR recognition is considered to 
represent a compromise between the need to provide host protection against 
virtually any pathogen-derived epitope and, at the same time, the need to 
ensure thymic positive selection and peripheral maintenance of this T-cell 
repertoire via intermediate affinity recognition of self-peptides that are 
presented by self-MHC molecules. Such degenerate specificity, however, also 
carries a certain risk for autoimmunity under special circumstances, e.g., 
strong innate immune activation. It has previously been shown in a number of 
animal models transgenic for human autoreactive T cell receptors that 
microbial peptides can induce MS-like disease through mechanisms of 
molecular mimicry [25], [26], [27].  
 
Mechanisms of epitope spreading. In addition to one TCR being engaged by 
different MHC/peptide complexes, one TCR specificity can set free epitopes 
for other TCRs, and result in a process called epitope spreading. Epitope 
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spreading describes the phenomenon observed in animal models of 
autoimmune diseases and cancer patients in which responses to 
immunodominant epitopes are elicited first, followed by responses to less 
dominant epitopes [28], [29], [30], [31], [32]. Although these examples 
document epitope spreading within autoantigens and to additional 
autoantigens, the inflammatory environment of viral infections could also 
support these immune response cascades by increasing the presentation of 
autoantigens, thereby spreading immune responses from foreign to self 
antigens.  
 
Mechanisms of bystander activation, polyspecific antigen 
recognition/molecular mimicry, and epitope spreading are not the only ways 
by which pathogens might trigger or accelerate CNS autoimmunity. Viral 
infections could also directly maintain autoreactive effector T cells or 
autoantigen-presenting cells. For example, Theiler's murine encephalomyelitis 
virus (TMEV)-induced demyelinating disease (TMEV-IDD) is a model of MS in 
which intracerebral TMEV infection of mice leads to an autoimmune 
demyelinating disorder 30–40 days after infection [33]. Persistent infection of 
microglial cells with TMEV has been shown to upregulate expression of MHC 
and co-stimulatory molecules and to enhance the ability of these cells to 
function as effective APCs [34]. Furthermore, Epstein Barr virus (EBV) 
immortalizes B cells and assists in their differentiation into long-lived memory 
B cells. These mechanisms could support the survival of autoreactive B cells 
or of a reservoir of APCs that can present autoantigens to promote 
autoimmunity [35] [36]. 
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Evidence for a biological role of these mechanisms mainly stems from 
experimental autoimmune disease models. Testing whether these 
mechanisms are indeed relevant in human autoimmune diseases such as MS 
is challenging due to a number of reasons including the following:  
 
1. Chronic autoimmune diseases are likely to become clinically apparent only 
after a considerable period of subclinical autoreactvity, at which time the 
pathogen might have already been cleared and/or the antiviral immune 
responses might have subsided.  
 
2. The proposed mechanisms by which a pathogen or a number of pathogens 
potentially initiate and sustain MS are likely dynamic, not mutually exclusive 
and might occur simultaneously or sequentially. A simple ‘one organism – one 
disease’ or ‘one mechanism – one disease’ paradigm might not apply to 
complex and heterogeneous diseases such as MS.  
 
3. The flip side of the idea that autoimmunity is driven by viral infections is that 
autoreactive immune responses, or even only a predisposition to the 
development of these responses, might affect the ability of the host to control 
infections and to regulate antiviral immune responses. The latter probably 
accounts for the occurrence of polyspecific antiviral humoral immune 
responses in the cerebrospinal fluid (CSF) compartment in patients with MS, 
which are characterized by intrathecal synthesis of IgG antibodies towards a 
variety of viruses including measles, rubella, varicella zoster virus and the 
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human herpesvirus 6 [37], [38], [39], [40], [41]. Intrathecal humoral immune 
response against measles, rubella and varicella zoster virus (MRZ reaction, 
MRZR) is present in 80-100% of patients with MS but less common in acute 
inflammatory diseases of the CNS [41]. Although these alterations could 
potentially be used as surrogate disease markers for diagnostic purposes, 
there is no evidence that they contribute to the initiation and progression of 
CNS tissue damage in MS [42]. 
 
The argument that infections contribute to disease development is strong for 
autoimmune conditions associated with one or two specific infectious agents 
such as Guillain-Barré Syndrom which is frequently preceded by 
Campylobacter jejuni infection or rheumatic fever after streptococcal infection. 
In contrast, MS as well as other major autoimmune diseases have been 
associated with a number of infectious agents. The ones that have received 
most attention during the past years are discussed below (Table 1).  
 
Herpesviruses  
Herpesviruses represent a group of large DNA viruses that are capable of 
establishing latency with potential for reactivation after primary infection, 
which typically occurs in childhood. Upon transmission to a naive host, the 
virus first amplifies the viral load through replicative (lytic) infection, then 
persists for the life of the host as an asymptomatic latent infection with 
occasional reactivations into lytic cycle, producing infectious virions 
transmissible to a new host. The mutual coexistence of human herpesviruses 
whether of the alpha [herpes simplex virus (HSV) types 1 and 2, varicella-
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zoster virus], beta [cytomegalovirus (CMV) and human herpesviruses 6 and 
7], or gamma [Epstein Barr Virus (EBV) and Kaposi's sarcoma–associated 
herpesvirus (KSHV)] subfamilies with their host depends on its ability to 
mount an appropriate virus-specific immune response, since most 
herpesvirus-associated diseases involve situations in which host responses 
either have been seriously compromised or have been unusually 
hyperactivated by the viral challenge [43]. Infection with VZV, HHV-6, and 
EBV have particularly been associated with MS.  
 
Varicella-zoster virus  
VZV is the causative agent of chickenpox, acquired by 95% of adults in the 
developed world [44]. The virus establishes latency in the dorsal ganglia of 
most healthy people [45], while zoster is the result of symptomatic viral 
reactivation that affects about 1% of the general population [46]. Even though 
many epidemiological studies link VZV to MS, a report evaluating 40 studies 
in the period 1965-99 indicated that there is insufficient evidence to support 
the association of MS with varicella or zoster infections [47]. Recent studies 
conducted by Sotelo and colleagues indicated presence of VZV DNA in CSF 
and mononuclear blood cells of MS patients in relapse [48], while VZV viral 
particles were observed by electron microscopy in patients’ CSF [49]. 
Conversely, another study failed to show presence of VZV virions, nor DNA in 
the CSF or in the acute plaques of MS patients [50]. Furthermore, 
recombinant antibodies prepared from clonally expanded plasma cells in MS 
CSF, which are thought to represent the intrathecally synthesized oligoclonal 
IgG, did not bind to VZV-infected cells [50]. Therefore, the role of VZV in MS 
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remains controversial and further studies with more rigorous methodologies 
are required to support the environmental role of VZV as a trigger of MS. 
 
Human Herpesvirus-6 
Research on HHV-6 involvement in MS has also been contradictory. This 
lymphotrophic herpesvirus, isolated in 1986 from patients with 
lymphoproliferative disorders [51], exhibits predominantly CD4+ T-lymphocyte 
tropism but has a tendency to infect neural cells, which renders it a potential 
suspect in the pathology of many neurological disorders [52].  Two virus 
variants have been identified, HHV-6B, associated with mesial temporal lobe 
epilepsy (MTLE), and HHV-6A which has primarily been associated with MS 
[53].  
DNA from HHV-6A was detected in brain tissue, serum, and CSF of 
some MS patients [54], [55], [56], [57]. Exacerbation of relapsing-remitting MS 
has been linked to higher viral loads in serum [58], [59] and in peripheral 
blood mononuclear cells (PBMCs) [60], suggesting association of HHV-6 
reactivation with disease relapses. This hypothesis is supported by 
observations of increased viral DNA and antigen levels in MS brain tissues 
[58]. Other reports suggested that constitutive presence of active HHV-6 
infection in glial cells in inflamed CNS tissue could result in virus-triggered 
immunopathologies in MS [61]. 
A mechanisms of molecular mimicry of the virus-encoded U24 protein 
and myelin basic protein (MBP), a putative MS-associated autoantigen, has 
been proposed based on amino acid sequence homology [62]. Even though 
cross-reactive T cells were identified in MS patients, they were also observed 
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to a lower frequency in controls [63]. Taken together, epidemiological data 
and the presence of active HHV-6 infection in some MS brain samples 
suggest a possible role for HHV-6 in perpetuating tissue damage in MS. 
 
Epstein Barr virus 
Another widespread herpesvirus is EBV (or HHV-4), which causes 
asymptomatic primary infection in early childhood or if acquired later in life 
leads to infectious mononucleosis (IM) in up to 25% of cases [64]. The virus 
establishes latency in B cells and is notorious for its tumorigenic potential. 
However, since the immune system constrains viral replication, malignancies 
occur mostly in cases of immunosuppression or of immunodeficiencies [43].  
Evidence for a potential role of EBV in the development of MS arises 
from reports on the positive correlation between clinical history of IM and MS 
occurrence [65], [66]. The risk of MS has been suggested to increase after IM 
and to persist for at least 30 years after infection [67]. A recent meta-analysis 
reviewed 14 studies, 11 case-control and 3 cohort studies, which investigated 
the association of IM and MS. The analysis concluded that the combined 
relative risk for development of MS after IM was 2.3 and in HLA-DR2 positive 
individuals even 7 [68], indicating that symptomatic EBV infection is a risk 
factor for MS [69]. These observations were confirmed by Ramagopalan et al. 
who compared more than 14,000 MS cases and 7,000 spouse controls. Their 
study found positive correlation of MS disease with history of IM, while no 
such association was observed for history of symptomatic measles, mumps, 
rubella, and varicella infections, or with history of measles, mumps, rubella, 
hepatitis B and influenza vaccination [70]. 
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Serological studies have demonstrated almost absolute, close to 
100%, EBV seropositivity in MS patients. However, high seropositivity, 
ranging between 90-95%, is also detected in the healthy adult population. A 
more prominent difference in seropositivity was observed in children with MS, 
83% of which were reported to be seropositive for EBV, compared to 42% of 
healthy age-matched controls [71]. Moreover, no significant difference in 
seropositivity was observed between the two groups for cytomegalovirus, 
parvovirus B19, and VZV. These results were confirmed by a German study, 
showing 98.6% EBV seropositivity in children with MS, contrasted to 72.1% in 
age-matched healthy controls [72]. Comparable results were observed by a 
more recent study that identified broadened and augmented recognition of the 
latency-associated EBV nuclear antigen 1 (EBNA1), suggesting dysregulation 
of EBV-specific immune responses in pediatric MS [73]. 
An age-dependent relationship was suggested between alterations in 
EBV-specific immune responses and clinical manifestation of MS [74]. A 
longitudinal study in 69 matched case-control sets of US military personnel 
investigated the presence of EBV antibodies prior to MS onset. While EBV-
specific antibody titers were similar between cases and people who 
developed MS before the age of 20, a two- to threefold increase in EBV-
specific antibody titers was observed in MS cases after the age of 25. The 
strongest risk factor, rising MS susceptibility tenfold, were increased titers of 
serum antibodies to EBV-derived nuclear antigens (EBNA), and in particular 
to the EBV nuclear antigen-1 (EBNA1) [74], [75]. A recent study confirmed 
these results by reporting that EBNA1-specific antibody responses occurred 
15 to 20 years before onset of symptoms in MS patients [76]. Even though, 
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these observations suggest an EBV-specific immune dysregulation preceding 
MS onset, a limitation of the abovementioned studies is that they compared 
EBV-specific responses only to HCMV responses and not to those towards 
other viruses, suspected in MS association.  
A more recent study determined immune responses to EBV, HHV-6, 
human cytomegalovirus (HCMV), influenza virus and measles virus antigens 
in a cohort of 147 patients with clinically isolated syndromes suggestive of MS 
(CIS) with a mean follow-up of 7 years compared to 50 demographically 
matched controls [77]. CIS patients showed increased humoral and cellular 
immune responses to EBNA1, but not to other EBV-derived proteins. IgG 
responses to other viral antigens and frequencies of T cells specific for HCMV 
and influenza virus gene products were unchanged in CIS patients. 
Furthermore, EBNA1 was the only viral antigen with which immune responses 
correlated with number of clinical disability and MRI metrics during the follow-
up period and increased EBNA1-specific IgG responses in CIS patients 
predicted conversion to clinically definite MS. Higher IgG responses to EBNA1 
in patients with CIS and relapsing-remitting MS (RRMS) were also reported to 
correlate with increased frequencies of EBV-specific CD8+ T cells [78]. In line 
with the results of the former study, Farrell et al. [79] found higher 
immunoglobulin G (IgG) responses to EBNA1 in CIS and RRMS patients, 
whereas responses to lytic EBV capsid antigens, HCMV, and measles-virus 
encoded proteins were unchanged compared to healthy blood donors. In 
these patients, elevated EBNA1-specific IgG responses were associated with 
the development of gadolinium-enhancing (Gd+) lesions and predictive for T2 
lesion volume change and clinical disability for a period of 5 years [79].  
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EBNA1 is the most consistently recognized EBV-specific antigen, 
which stimulates CD4+ T cell responses in healthy virus carriers. Selective 
expansion of T cells specific for EBNA1 was observed in MS patients [80], 
[81]. Moreover, a small subset of them have been shown to cross-react with 
myelin antigens, supporting the hypothesis that clonally expanded EBNA1-
specific T cells could be actively involved in MS immunopathology by 
stimulating cross-recognition through molecular mimicry [81].   
Molecular mimicry is one of the classical paradigms for infection-
induced autoimmunity and there is solid evidence form a number of animal 
models transgenic for human autoreactive T cell receptors that microbial 
peptides can induce MS-like disease through mechanisms of molecular 
mimicry [25], [26], [27]. An alternative hypothesis for the association of EBV 
infection and autoimmune diseases is based on the virus` ability to 
immortalize B cells and to assists in their differentiation into long-lived 
memory B cells. Indeed, there is evidence that the EBV-encoded proteins 
LMP1 and LMP2 mimic signals of T-cell help and B-cell receptor engagement, 
respectively, possibly rendering autoreactive B cells less susceptible to 
tolerance control in the periphery [82]. These mechanisms could support the 
survival of autoreactive B cells or of a reservoir of APCs that can present 
autoantigens to promote autoimmunity [35] [36].  
B cells are now recognized to play a critical role in the pathogenesis of 
MS and increasing number of compounds that deplete B cells or target 
pathways essential for B cell development and function are currently being 
tested for their potential use as MS therapeutics. Serafini and colleagues 
found that EBV-infected B cells expressing viral antigens are significantly 
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enriched in postmortem brain samples from patients with MS, but not in brain 
samples from patients with other inflammatory CNS diseases [83]. Activated 
CD8+ T cells where also present close to EBV-infected B-cell foci, suggesting 
that EBV-specific lymphocyte responses may be involved in MS 
immunopathologies. However, these findings could not be reproduced in 
several subsequent studies [84] [85] [86]. Further research should clarify the 
source of this discrepancy. At present, the aforementioned conflicting data on 
the presence of EBV in MS brain tissue do not allow to draw definite 
conclusions on the frequency and potential function of EBV-infected B cells in 
the CNS of patients with MS. 
Taken together, there is strong epidemiological evidence for a link 
between symptomatic EBV infection and MS development. The immune-
modifying function of EBV suggests that this virus is, indeed, a major 
candidate for triggering MS. The mechanisms responsible for this association 
are, however, far from understood.  
 
Human endogenous retroviruses  
Human endogenous retroviruses (HERVs), comprising about 8% of the 
human genome, are remnants of ancestral germ-line infections by 
retroviruses [87]. A founding member of the HERV-W family, known as MS-
associated retroviral agent (MSRV), is presumably a complete replication-
incompetent virus capable of forming extracellular infectious virions [88], [89]. 
MSRV has been repeatedly isolated from CSF and blood of MS patients [90], 
[91], as well as from body fluids of individuals with other neuroinflammatory 
disorders, but is less frequently observed in healthy controls [92]. Notably, 
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MSRV has been shown to encode a protein that displays pro-inflammatory 
and superantigenic activity for CD4+ T cells [93]. The immunopathogenicity of 
activated T cells was confirmed in an in vivo study, in which severe combined 
immunodeficiency (SCID) mice with engrafted human immune system 
components were injected with MSRV virions and presented with acute 
neurological symptoms [94].  
Interestingly, the HERV-W provirus is located on chromosome 14q11.2 
region within a T-cell - receptor, whereas a different HERV-H family 
provirus, also expressed in cells of MS patients [95], is located on 
chromosome 7q21-22 region. These two chromosomal regions correspond to 
genetic loci that have been associated with predisposition to MS [96].  
In addition, a study by Sutkowski and colleagues reported that the env 
gene of HERV-K18, possessing superantigenic activity, was transcriptionally 
activated by EBV. These observations suggest that superantigen-stimulated T 
cell activation could potentially have a role in EBV infection and associated 
diseases [97], [98]. There is increasing interest in the study of HERVs as 
causal factors in MS. Recent findings identify herpesviruses, including EBV 
and HHV-6 [99], [100], as potential inducers of HERV activation, alluding to 
the involvement of more than one infectious agents as triggers of MS. 
However, more studies are needed to confirm this hypothesis.   
 
Torque Teno virus 
Not only pathogenic, but also non-pathogenic infectious agents have been 
suggested to be involved in exacerbation and/or induction of MS. The Torque 
Teno virus (TTV), claimed to have a prevalence rate of 72-100% in the 
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general population [101], has been shown to establish persistent infection 
without significant clinical phenotype [102]. A study by Sospedra and 
colleagues determined the specificity of clonally expanded T cells from CSF of 
MS patients during disease exacerbation. These T cells were shown to 
recognize poly-arginine regions of TTV as well as evolutionary conserved 
motifs of other common viruses and prokaryotes, suggesting a mechanism of 
misdirected autoantigen response as a result of molecular mimicry [103]. 
However, due to the paucity of data, the relation of TTV infection and MS 
remains ill-defined.  
 
6. Conclusions and Future Perspectives  
The relationship between infections and autoimmune diseases is complex and 
the mechanisms by which infectious pathogens could trigger MS are likely 
dynamic, i.e. they might change over time and not be mutually exclusive. 
Epidemiological observations indicate that viral infections could contribute to 
MS development not only as triggers of disease exacerbations, but also as 
etiological agents, i.e. long before the disease becomes clinically apparent.  
The two to three folds increased risk of developing MS among individuals with 
history of IM compared with subjects who acquired EBV without symptoms, 
the almost universal seropositivity for EBV in adults and children with MS, and 
the steep and monotonic increase in MS risk with increasing titers of 
antibodies to EBV in apparently healthy adults could suggest that EBV 
infection is causally linked to MS development.  The mechanisms responsible 
for this association are far from understood. Moreover, the incidence of IM in 
Western countries (≥ 5%) [64] exceeds the prevalence of MS in comparable 
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populations (0.1%) by far (more than 50-fold) suggesting that yet unidentified 
genetic and/or additional environmental factors determine whether 
symptomatic EBV infection indeed predisposes to MS.  
 
Although one particular MS-causing agent might still be discovered, current 
data suggest that multiple infections along with non-infectious environmental 
factors trigger the development of MS. These factors are likely ubiquitous, i.e. 
highly prevalent in the general population, and they require a permissive 
genetic background that predisposes for MS development. Future studies 
investigating infectious pathogens in a complex and heterogenous disease 
such as MS will benefit from careful and detailed clinical, pathological and 
neuroimaging-based patient characterizations and from reproducibility in 
different study populations. In addition, novel humanized animal models of 
autoimmune diseases that are simultaneously permissive for viral pathogens 
which usually infect only humans [104], [105] should allow investigation of 
specific aspects of host-pathogen interactions during autoimmune CNS 
inflammation in vivo. The integration of these data might eventually allow us to 
better define the role of viruses in the etiology and pathogenesis of MS and 
how virus-host interactions could be targeted for MS therapy [106]. 
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Table 1. Viral agents suspected as triggers of multiple sclerosis.  
Virus Evidence for Association Reference 
Herpesviruses   
acquired earlier in life by MS patients  [107] 
reactivation linked to MS exacerbation [108] 
viral DNA isolated from blood and CSF  [48] 
VZV 
 
virions observed by electron microscopy in 
CSF (inconsistent observations) 
[49], [50] 
isolated from blood, CSF, and brain tissue  [54], [55] 
presence of anti-viral antibodies in blood and 
CSF (inconsistent observations) 
[56], [57] 
increased viral loads linked to MS 
exacerbation 
[58], [59] 
HHV-6 
cross-reactivity between virus-specific T cells 
and myelin antigens  
[62], [63] 
near absolute seropositivity in children and 
adults with MS 
[71], [72], [73] 
increased risk of MS in individuals with 
history of infectious mononucleosis 
[65], [66], [69] 
virus reactivation linked to disease activity in 
early MS  
[109] 
increased EBNA1-specific antibodies prior to 
MS onset 
[75], [74], [76] 
cross-reactivity of clonally expanded EBNA1-
specific T cells with myelin antigens 
[80], [81] 
EBV 
enrichment of EBV-infected B cells in MS 
brain tissues 
[83] 
Retroviruses   
isolated from blood and CSF of MS patients [90], [91] 
encode for proteins with superantigenic 
activity 
[93] 
chromosomal loci identified as MS 
susceptibility regions 
[95], [96] 
HERV-W 
(MSRV) 
virions trigger acute neurological symptoms 
in mice 
[94] 
Other agents   
Torque Teno 
virus 
clonally expanded T cells from CSF of MS 
patients recognize viral motifs 
[103] 
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Figure Legend 
 
 
Figure 1: Molecular mechanisms of pathogen-induced autoimmunity. (A) 
Pathogen-activated antigen-presenting cells can display self antigens from 
dying cells to autoreactive T lymphocytes in a process known as bystander 
activation. (B) Activation of the immune system resulting from stimulation of 
pattern recognition receptors by infectious agents can lead to expression of 
pro-inflammatory mediators and triggering of autoreactive lymphocytes. (C) 
Microbial superantigens cross-link MHC class II molecules with TCRs 
inducing antigen unspecific activation of autoreactive T cells. (D) Certain 
pathogen-derived antigens share structural similarities with self peptides 
causing activation of autoreactive T cells through molecular mimicry. (E) The 
process of epitope spreading can enhance autoimmune responses by 
activating autoreactive T cells to ‘new’ self antigens during the progression of 
the disease. (F) Viral agents can enhance the activation state of autoantigen 
presenting cells and induce the survival of autoreactive lymphocytes. As an 
example, persistent infection of microglial cells with Theiler's murine 
encephalomyelitis virus (TMEV) was shown to upregulate expression of MHC 
and co-stimulatory molecules and enhance the ability of these cells to function 
as effective APCs [34]. Furthermore, EBV infection could assist in the survival 
of autoreactive B cells [36]. APC - antigen-presenting cell; MHC – major 
histocompatibility complex; PAMP - pathogen-associated molecular pattern; 
TCR – T cell receptor; TLR - Toll-like receptor. 
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